IKT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
22.2M
+5.6%
21.1M
+18.0%
17.8M
+29.5%
13.8M
+7.9%
12.8M
R&D
15.0M
+12.0%
13.4M
+23.6%
10.8M
+70.5%
6.4M
-16.9%
7.6M
SG&A
7.2M
-5.6%
7.7M
+3.8%
7.4M
+8.9%
6.8M
+20.7%
5.6M
Operating Income
-22229057
-5.6%
-21050995
-18.0%
-17841919
-29.5%
-13775626
-7.9%
-12768373
EBITDA
-22229057
-5.6%
-21050995
-18.0%
-17841919
-29.5%
-13775626
-8.1%
-12744686
Net Income
-20467334
-4.5%
-19591231
-19.6%
-16380840
-28.6%
-12734651
-6.7%
-11930280
EPS (Basic)
$-0.10
+9.1%
$-0.11
-10.0%
$-0.10
+0.0%
$-0.10
+23.1%
$-0.13
EPS (Diluted)
$-0.10
+9.1%
$-0.11
-10.0%
$-0.10
+0.0%
$-0.10
+23.1%
$-0.13
Shares (Diluted)
196.9M
+12.8%
174.6M
+1.3%
172.3M
+39.4%
123.6M
+37.3%
90.1M
Inhibikase Therapeutics (IKT) — Financials